{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:06:18Z","timestamp":1784307978404,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bulcan.2026.03.008","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:21:34Z","timestamp":1783336894000},"page":"888-897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u00c9volution de la prise en charge des cancers uroth\u00e9liaux m\u00e9tastatiques"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4130-4839","authenticated-orcid":false,"given":"Cl\u00e9mentine","family":"Gaucher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Vicier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2026.03.008_bib0150","unstructured":"INCA, 2015, available from: URL: https:\/\/www.cancer.fr\/personnes-malades\/les-cancers\/vessie\/comprendre-la-maladie\/facteurs-de-risque."},{"key":"10.1016\/j.bulcan.2026.03.008_bib0155","unstructured":"Global Cancer Observatory, 2022, available from: URL: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/30-bladder-fact-sheet.pdf."},{"issue":"19","key":"10.1016\/j.bulcan.2026.03.008_bib0160","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100\u00a0Trial After\u00a0\u2265\u00a02\u00a0years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2026.03.008_bib0165","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.bulcan.2026.03.008_bib0170","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2\u00a0study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2026.03.008_bib0175","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.bulcan.2026.03.008_bib0180","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.bulcan.2026.03.008_bib0185","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O\u2019Donnell","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2026.03.008_bib0190","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39\u00a0trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2026.03.008_bib0195","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.annonc.2025.04.009","article-title":"Bulumtatug fuvedotin (BFv, 9MW2821), a next-generation nectin-4\u00a0targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I\/II study","volume":"36","author":"Zhang","year":"2025","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2026.03.008_bib0200","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1158\/1535-7163.MCT-22-0743","article-title":"Preclinical evaluation of 9MW2821, a site-specific monomethyl auristatin E-based antibody \u2013\u00a0drug conjugate for treatment of nectin-4\u00a0\u2013 expressing cancers","volume":"22","author":"Zhou","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bulcan.2026.03.008_bib0205","doi-asserted-by":"crossref","first-page":"858865","DOI":"10.3389\/fonc.2022.858865","article-title":"Head-to-head comparison of the expression differences of NECTIN-4, TROP-2, and HER2\u00a0in urothelial carcinoma and its histologic variants","volume":"12","author":"Fan","year":"2022","journal-title":"Front Oncol"},{"issue":"16","key":"10.1016\/j.bulcan.2026.03.008_bib0210","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bulcan.2026.03.008_bib0215","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","article-title":"TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes","volume":"35","author":"Loriot","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2026.03.008_bib0220","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.03.008_bib0225","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.annonc.2023.09.3114","article-title":"The double antibody drug conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma","volume":"35","author":"McGregor","year":"2024","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2026.03.008_bib0230","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2026.03.008_bib0235","doi-asserted-by":"crossref","first-page":"1011885","DOI":"10.3389\/fonc.2022.1011885","article-title":"HER2\u00a0expression in urothelial carcinoma, a systematic literature review","volume":"12","author":"Scherrer","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.03.008_bib0240","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2014.10.009","article-title":"Multicentre randomised phase II trial of gemcitabine\u00a0+\u00a0platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing HER2","volume":"51","author":"Oudard","year":"2015","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2026.03.008_bib0245","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02\u00a0phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.bulcan.2026.03.008_bib0250","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-24-1513","article-title":"Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: analysis of the phase Ib DS8201-A-U105\u00a0study","volume":"30","author":"Hamilton","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.bulcan.2026.03.008_bib0255","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","article-title":"Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib\/II dose-escalation and dose-expansion study","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.bulcan.2026.03.008_bib0260","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bulcan.2026.03.008_bib0265","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.euo.2020.12.007","article-title":"Genetic differences between bladder and upper urinary tract carcinoma: implications for therapy","volume":"4","author":"Sfakianos","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"21","key":"10.1016\/j.bulcan.2026.03.008_bib0270","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2026.03.008_bib0275","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-00826","article-title":"Erdafitinib or erdafitinib plus cetrelimab for patients with metastatic urothelial carcinoma and FGFR alterations: final results from the phase II NORSE study","author":"Loriot","year":"2026","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2026.03.008_bib0280","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jamaoncol.2024.3900","article-title":"Rogaratinib plus atezolizumab in cisplatin-ineligible patients with FGFR RNA-overexpressing urothelial cancer: the FORT-2\u00a0phase 1b nonrandomized clinical trial","volume":"10","author":"Sweis","year":"2024","journal-title":"JAMA Oncol"},{"issue":"21","key":"10.1016\/j.bulcan.2026.03.008_bib0285","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"Von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.bulcan.2026.03.008_bib0290","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126002249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126002249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:29:32Z","timestamp":1784305772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126002249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0007455126002249"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.03.008","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c9volution de la prise en charge des cancers uroth\u00e9liaux m\u00e9tastatiques","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer.","name":"copyright","label":"Copyright"}]}}